A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01783678 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C
Human Immunodeficiency Virus

Interventions

DRUG: Sofosbuvir
DRUG: RBV

Sponsor

Gilead Sciences